Commenting on the investment, Penn Pharma chief executive officer Richard Yarwood said the move was fuelled by its demonstrated ability to provide pragmatic and timely solutions for their needs.
"At a time when many businesses are struggling we are continuing to grow the Penn business and our recent investments give us the platform to provide even better services to our customers," Yarwood added.
Earlier this year, the company had built a new 15,000ft2 site for the clinical and commercial manufacture of tablets and capsules.
Around £14m was invested on the solid dose contained manufacturing facility, which has started operations to handle potent active pharmaceutical ingredients.
With the latest investment, Penn Pharma will remain positioned to address the formulation and both clinical and commercial manufacturing needs of its clients.